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Abstract 
Purpose: This study was performed to compare the cytotoxicity and magnetic resonance (MR) 
contrast in diverse cultured cells and xenograft tumors models of two ultra-small superpara-
magnetic iron oxides (USPIOs), thermally cross-linked superparamagnetic iron oxide nanoparti-
cles (TCL-SPION) and monocrystalline iron oxide nanoparticles (MION-47). 
Materials and methods: Transmission electron microscopy (TEM) images and R2 relaxivity 
values of the TCL-SPION and MION-47 were obtained and the cell viability and cell growth ve-
locity of treated and untreated human  fibroblasts and human umbilical vein endothelial cells 
(HUVEC) were evaluated. The effect of TCL-SPION and MION-47 on the secretion of interlukin-6 
(IL-6) and tumor necrosis factor-alpha (TNF-α), the production of nitric oxides and the mito-
chondrial membrane potentials in murine macrophage cells (RAW264.7) was compared. Human 
hepatocellular carcinoma cells (HepG2, 5x10
5) were subcutaneously injected into nude mice 
(BALB/c)  and in vivo MR  imaging  of  tumors  before  and  after  injection  with  TCL-SPION  or 
MION-47 (12.5 mg Fe/kg) was performed on a 1.5 Tesla MRI scanner. 
Results: On TEM images, the average core diameter of TCL-SPION was 9 nm whereas that of 
MION-47 was 5 nm. TCL- SPION (345.0 ± 6.2 mM
-1sec
-1) had higher relaxivity (R2) than MION-47 
(130.7 ± 1.1 mM
-1sec
-1). Significant changes in cell viability and growth were not found in human 
fibroblasts and HUVEC exposed to TCL-SPION and MION-47. However, IL-6 and TNF-α se-
cretions increased dose-dependently and significantly in the macrophages treated with MION-47 
or TCL-SPION. TCL-SPION had a lower stimulatory effect on IL-6 secretions than did MION-47 
(P <0.05) and nitric oxides were produced in the macrophages by MION-47 but not TCL-SPION. 
A change in the mitochondrial membrane potential of the macrophages was observed 24 hours 
after the exposure, and MION-47 induced more collapses of the mitochondrial membrane po-
tential than did TCL-SPION. In the in vivo MR imaging, 33.0  1.3% and 7.5  0.4% signal intensity 
decrease on T2*-weighted images was observed in the tumors injected with TCL-SPION and 
MION-47, respectively.  
Conclusion: Due to the modified surface properties and larger core size of its iron oxide na-
noparticles,  TCL-SPION  achieves  lower  cytotoxicity  and  better  tumor  MR  contrast  than 
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MION-47. Our study suggests that TCL-SPION may be used as a new platform for tumor imaging 
and therapy monitoring. 
Key words: Ultra-small superparamagnetic iron oxides, Magnetic resonance imaging, TCL-SPION, 
MION-47, Tumor targeting. 
Introduction 
Ultra-small  superparamagnetic  iron  oxide 
(USPIO, <50 nm) is appears to be suitable for the sin-
gle particle platform to assess targeting imaging and 
therapy in vivo [1-3]. Monocrystalline iron oxide na-
noparticle (MION-47, 20−25 nm overall diameter) is a 
commercially available [4] and has been widely used 
to assess functional MR imaging [5], vascular imaging 
[6],  and  measurement  of  macrophage  activity  in  a 
number  of  diseases  [7].  However,  tumor  targeting 
effect of MION-47 is limited and serious side effects of 
these USPIO have been reported in clinical trials for 
evaluation of nodal metastases in known cancer pa-
tients [8-10]. Recently our group developed a novel 
USPO, thermal cross-linked superparamagnetic iron 
oxide  nanoparticle  (TCL-SPION,  20−30  nm  overall 
diameter) which is synthesized by a simple thermal 
cross-linking  method  using  Si-OH-containing  co-
polymer [11]. TCL-SPION has been applied as mul-
ti-functional  nanoparticle  for  metastatic  tumors  im-
aging in lymph nodes [12], for targeted cancer therapy 
by conjugation  with cancer-specific ligands and an-
ti-cancer drugs [13, 14], for in vivo bimodal imaging by 
combination  with  optical  probes  [11]  and for  genes 
delivery [15].  
In contrast to the prototype dextran coating of 
MION-47 [8], the surface of TCL-SPION was specifi-
cally  modified  with  the  protein-  or  cell-resistant 
polymer,  poly(TMSMA-r-PEGMA-r-NAS)  [16].  The 
surface modification of nanoparticles provides mainly 
the benefits of protection from rapid degradation and 
aggregation, reduction in toxicity and improved the 
enhanced permeability and retention (EPR) effect for 
tumor targeting in vivo [17-20]. Furthermore, the ad-
justing  surface  coating  thickness  and  materials  can 
affect the magnetic property of nanoparticles [21]. The 
diverse cytotoxic properties of these nanoparticles by 
the  modification  of  surface  coating  have  been  re-
ported. For example, the accumulated nanoparticles 
diminished the cell proliferation and viability result-
ing  from  cytoskeletal  changes  and  reactive  oxygen 
species (ROS) production [22, 23]. The degraded na-
noparticles also affected cellular function and home-
ostasis [24-28].  
Various nanoparticles are under development as 
molecular imaging agents for the detection of tumors 
and treatment monitoring. In prior to biomedical ap-
plication of novel nanoparticles, however, the toxico-
logical effect and the biodistribution of nanoparticles 
should be carefully evaluated.  In present study, we 
evaluated  the  magnetic  properties,  the  cytotoxicity 
and the tumor imaging efficiency of a novel iron oxide 
nanoparticle,  TCL-SPION  compared  with  MION-47 
as a reference. TCL-SPION exhibited higher relaxivity 
(R2  value),  lower  cytotoxicity  in  cultured  cells  and 
more  intense  MR  contrast  effects  in  tumor  imaging 
than did MION-47.  
Materials and Methods 
USPIOs and in vitro MR imaging 
The  TCL-SPION  was  obtained  from  the 
Gwangju Institute of Science and Technology (GIST). 
The  MION-47  was  purchased  from  CMIR,  Massa-
chusetts General Hospital of Harvard University. The 
in vitro MR imaging of the phantoms associated with 
varying  concentrations  of  nanoparticles  was  per-
formed using a 3 Tesla clinical MR scanner (Siemens 
Healthcare,  Erlangen,  Germany).  For  measurements 
of the R2 values, a multiple spin-echo sequence with a 
repetition time (TR) of 5000 ms and a viable echo time 
(TE, 16, 32, 48, 64 ms) was used. The common acqui-
sition parameters were as follows: field of view (FOV) 
= 147 × 157 mm, and matrix size = 320 × 300. 
Cell culture 
Human fibroblasts isolated from dermis and pe-
ripheral blood monocytes were cultured in Dulbecco's 
modified  Eagle  medium  (WelGENE,  Daegu,  Korea) 
supplemented  with  10%  FBS  (WelGENE)  and  a  1% 
antibiotic solution containing penicillin and strepto-
mycin.  Human  umbilical  vein  endothelial  cells 
(HUVEC) were cultured in an endothelial cell growth 
medium EGM-2 MV BulletKit (Lonza, Verviers, Bel-
gium)  on  a  gelatin-coated  culture  dish.  RAW264.7 
mouse  macrophage  cells  and  Hep  G2  human  liver 
cancer cells were cultured in RPMI 1640 (WelGENE) 
with 10% FBS and 1% penicillin and streptomycin. All 
the cells were cultured in a 5% CO2 incubator at 37C.  
Cell viability and growth 
To evaluate the cytotoxicity of TCL-SPION and 
MION-47, human fibroblasts, HUVEC and RAW264.7 
cells  were  incubated  in  medium  containing Theranostics 2012, 2(1) 
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TCL-SPION or MION-47 (10, 25, 50, 100, 250, 500, 1000 
µg  Fe/mL)  for  24  hours,  and  cell  viability  was  as-
sessed by flow cytometry analysis using 7-AAD (BD 
PharmingenTM,  Franklin  Lakes,  NJ,  USA).  The 
cell-associated  fluorescence  was  measured  using  a 
FACSCalibur  flow  cytometer  (BD  Biosciences).  The 
data were analyzed with the CellQuest v3.3 software 
(BD Biosciences). 
To  evaluate  the  influence  of  TCL-SPION  and 
MION-47  on  cell  growth,  human  fibroblasts  and 
HUVEC were seeded in 6-well tissue culture plates at 
1  ×  104  cells/well  and  were  further  cultured  after 
adding  100  µg  Fe/mL  of  TCL-SPION  or  MION-47. 
The number of cells cultured with or without USPIO 
was counted on days 1, 2 and 3 using a hemocytome-
ter. 
Cytokines secretion and nitric oxide production 
in macrophage 
An  enzyme-linked  immunospecific  assay 
(ELISA) was performed  to evaluate whether USPIO 
elicits  the  production  of  the  proinflammatory  cyto-
kines in macrophages. In brief, RAW264.7 cells were 
seeded  in  a  24-well  tissue  culture  plate  at  5  ×  104 
cells/well.  After  treatment  with  TCL-SPION  or 
MION-47 at concentrations of 25 µg Fe/mL and 50 µg 
Fe/mL for 24 hours, the levels of interleukin-6 (IL-6) 
or  tumor  necrotic  factor-alpha  (TNF-α)  secreted  by 
RAW264.7  were  measured  using  an  enzyme-linked 
immunosorbent  assay  kit  (R&D,  Minneapolis,  MN, 
USA).  
To investigate the effect of USPIO on nitric oxide 
production  in  mouse  macrophages,  nitrite  was  as-
sayed by the Griess reaction [27]. Briefly, the culture 
supernatants  from  the  RAW264.7  cells  treated  with 
TCL-SPION or MION-47 at concentrations of 25 µg 
Fe/mL, 50 µg Fe/mL and 100 µg Fe/mL for 24 hours 
were collected, and 100 µl of the Griess reagent (0.5% 
sulfanilamide,  0.05%  N-(1-Naphthyl)  ethylenedia-
mine and 2.5% phosphoric acid) was added to 100 µl 
of the supernatant in a 96-well plate. The absorbance 
was measured at 540 nm using a microplate reader, 
and  the  nitrite  concentration  was  calculated  from  a 
standard sodium nitrite curve. 
Mitochondrial membrane potential 
To  evaluate  the  changes  in  the  mitochondrial 
membrane potential of macrophage cells treated with 
TCL-SPION  or  MION-47,  the  fluorescence  of  JC-1 
(Molecular  Probes,  Eugene,  OR,  USA),  which  fluo-
resces differently in healthy cells with the intact mi-
tochondria  and  apoptotic  cells  in  which  the  mito-
chondrial  membrane  potential  has  collapsed,  was 
analyzed. In healthy cells, JC-1 is taken up by the mi-
tochondria, where it forms aggregates exhibiting in-
tense red fluorescence. In cells with depolarized mi-
tochondria potential, JC-1 remains in the cytoplasm, 
where it fluoresces green. 
In  brief,  after  treatment  with  TCL-SPION  or 
MION-47  at  concentrations  of  50  µg  Fe/mL  for  24 
hours,  RAW264.7  cells  were  incubated  in  a  buffer 
containing 2 μM of JC-1 for 15–20 minutes at 37℃. The 
JC-1 stained cells were suspended in the culture me-
dia and immediately analyzed using flow cytometry 
or fluorescence microscopy. The  images of the cells 
were acquired with a fluorescence microscope (Leica, 
Wetzlar,  Germany)  equipped  with  a  CCD  camera 
(Leica). The cell fluorescence was concomitantly as-
sessed with a FACSCalibur flow cytometer (BD Bio-
sciences). 
Measurement of total cellular iron levels 
The cellular iron levels were measured using the 
Total Iron Reagent Set (Pointe Scientific, Canton, MI, 
USA).  Briefly,  the  cells  were  incubated  in  medium 
supplemented with USPIO (0, 50, 100, 200 μg Fe/mL) 
for 24 hours. After washing with PBS twice, the cells 
were  enumerated.  The  collected  cells  were  resus-
pended  in  6  N  HCl  and  incubated  at  70C  for  30 
minutes. The total iron levels were measured accord-
ing to the manufacturer's instructions, and the aver-
age cellular iron concentration was calculated by di-
viding the total mean values by the number of cells. 
In vivo MR imaging 
To  develop  the  tumor  model,  approximately 
6-week  old  BALB/c-nude  mice  were  anesthetized, 
and 5 × 105 Hep G2 cells suspended in 0.1 mL matrigel 
(BD  Biosciences)  were  subcutaneously  injected  into 
the back right flank.  
When  the  tumor  reached  5-8  mm  diameter  as 
measured with a digital caliper, in vivo MR imaging 
studies  were  performed  using  a  1.5T  clinical  MR 
scanner  (Sigma  Horizon;  GE  Medical  Systems,  Mil-
waukee, WI) with a human wrist coil after tail vein 
injection of 5, 12.5, 30 mg Fe/kg of USPIOs. The MR 
images of the tumors were obtained before and at 4 
and  24  hours  after  the  intravenous  injection  using 
gradient echo sequence (TR = 12.5 ms, TE = 5.9 ms, 
FOV = 70 × 70, flip angle = 15°, matrix = 256 × 256, 
NEX  =  2.0  and  section  thickness  =  2  mm)  and  3D 
FIESTA-COR pulse sequence (TR=7.7 ms, TE = 3.2 ms, 
FOV = 80 × 80, flip angle = 45°, matrix = 190 × 190, 
NEX = 2.0 and section thickness = 2 mm).  
To determine the signal intensity (SI) changes in 
the  MR  images  of  the  tumors,  regions  of  interest 
(ROIs) were drawn along the margin of each tumor 
and  the  left  thigh  muscle  on  representative  T2*- Theranostics 2012, 2(1) 
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weighted MR images. The ratio of SI changes for tu-
mor  versus  muscle  was  calculated  according  to  the 
formula: 
SI ratio = [SI tumor (post-USPIO) / SI muscle (post-USPIO)] / [SI 
tumor (pre-USPIO) / SI muscle (pre-USPIO)] 
Prussian blue staining and immunostaining 
To  examine  the  intracellular  distributions  of 
TCL-SPION  and  MION-47,  the  TCL-SPION  and 
MION-47 treated cells were fixed in 4% paraformal-
dehyde and stained with Prussian blue. Briefly, the 
fixed cells were washed 3 times with PBS, incubated 
for 30 minutes with 5% potassium ferrocyanide (Sig-
ma,  St.  Louis,  MO,  USA)  in  5%  hydrochloric  acid, 
rewashed  and  counterstained  with  nuclear  fast  red 
(Sigma) for 20 minutes. 
After  the  MR  imaging  was  completed,  the  tu-
mor-bearing  mice  were  sacrificed  and  the  tumors 
were  carefully  removed.  The  tumors  were  fixed  in 
10% formalin, embedded in regular paraffin wax and 
cut  into  4  μm  sections.  The  paraffin  sections  were 
dewaxed and hydrated. The presence of TCL-SPION 
or MION-47 in tumor sections was detected by Prus-
sian blue staining. Macrophages were detected using 
antibodies  for  CD  68  (Santacruz,  Santa  Cruz,  CA, 
USA). After incubation with the appropriate second-
ary  antibody,  the  sections  were  stained  with  dia-
minobenzidine solution (Dako, Hamburg, Germany) 
for 2–5 minutes.  
Statistical analysis 
Means ± standard errors were calculated from at 
least three independent experiments and statistically 
evaluated using a one-way ANOVA model followed 
by  the  Student-Newman-Keuls  test.  For  all  tests, 
p-values  less  than  0.05  were  considered  statistically 
significant. 
 
Results 
Comparison of the magnetic properties of 
TCL-SPION and MION-47  
The  schematics  of  TCL-SPION  and  MION-47 
and physicochemical parameters are shown in Figure 
1A. 
 
 
Figure  1.  Physicochemical  parameters  and  comparison  of  magnetic  properties.  (A)  A  schematic  representation  of 
TCL-SPION and MION-47. (B) TEM image of TCL-SPION and MION-47. (C) A T2-weighted MR image of TCL-SPION and MION-47 at 
various iron oxide concentrations. At identical iron oxide concentrations, TCL-SPION had a more intense MR contrast effect than 
MION-47. (D) Plots of the R2 (1/T2) value. The relaxivity (R2) of TCL-SPION (345.0 ± 6.2 mM-1sec-1, blue) was higher than that of 
MION-47 (130.7 ± 1.1 mM-1sec-1, red). Theranostics 2012, 2(1) 
 
http://www.thno.org 
80 
From  transmission  electron  microscopy  (TEM) 
images, the average core diameter of TCL-SPION was 
9 nm, whereas that of MION-47 was 5 nm. The relax-
ivities  (1/T2=R2)  of  TCL-SPION  and  MION-47  dis-
persed  in  distilled  water  were  measured  using  a  3 
Tesla  MR  scanner.  The  R2  of  TCL-SPION  and 
MION-47 were 345.0 ± 6.2 mM-1sec-1 and 130.7 ± 1.1 
mM-1sec-1,  respectively.  At  identical  iron  concentra-
tions, TCL-SPION showed the more intense MR con-
trast effect compared to MION-47 (Fig. 1B).  
In vitro evaluation of cytotoxicity in human 
normal cells 
To compare the cellular toxicities of TCL-SPION 
and  MION-47,  we  first  evaluated  cell  viability  in 
normal human cells (human fibroblasts and HUVEC). 
A reduction in human fibroblasts and HUVEC viabil-
ity  was  not  observed  after  24  hours  of  exposure  to 
increasing  concentrations  of  TCL-SPION  and 
MION-47  (up  to  1  mg  Fe/mL)  (Fig.  2A,  B). 
TCL-SPION and MION-47 (up to 1 mg Fe/mL) were 
not taken up by the human fibroblasts and HUVEC 
(Supplementary  Material:  data  1).  When  human  fi-
broblasts and HUVEC were exposed to 100 µg Fe/mL 
of  TCL-SPION  or  MION-47  separately  for  3  days, 
there was no effect on the cell growth velocity (Fig. 2C, 
D). 
In vitro evaluation of cytokines release and nitric 
oxide production in macrophages 
We compared the influences of TCL-SPION and 
MION-47  on  proinflammatory  cytokine  release  in 
mouse macrophage cells. The RAW264.7 cells phag-
ocytized  the  TCL-SPION  and  MION-47  within  2 
hours. There was no significant difference in the ac-
cumulation of two USPIOs in the RAW264.7 cells until 
24 hours (Supplementary Material: data 2, P > 0.05). 
The IL-6 and TNF-α releases in the RAW264.7 cells 
were dose-dependently and significantly increased by 
adding  TCL-SPION  and  MION-47  (Fig.  3A,  B,  P  < 
0.001). MION-47 showed a greater stimulatory effect 
on  IL-6  release  than  did  TCL-SPION  (Fig.  3A). 
TCL-SPION  and  MION-47  showed  similar  stimula-
tory effects on TNF-α (Fig. 3B).  
The effect of TCL-SPION and MION-47 on nitric 
oxide production in macrophages was also evaluated. 
MION-47 induced a dose-dependent and significant 
increase in nitric oxide production (Fig. 3C, P < 0.001). 
However, TCL-SPION did not have any stimulatory 
effects  on  nitric  oxide  production  in  the  RAW264.7 
cells (Fig. 3C).  
 
Figure 2. In vitro evaluation of cytotoxicity in human normal cells. (A, B) The viabilities of human fibroblasts and human umbilical 
vein endothelial cells (HUVEC) were assessed by MTT assay. A reduction in the viability of human fibroblasts and HUVEC was not 
observed after 24 hours of exposure to increasing concentrations of TCL-SPION and MION-47 (up to 1 mg Fe/mL). (C, D) The growth 
velocity was assessed by a trypan blue assay. The human fibroblasts and HUVEC were exposed to 100 µg Fe/mL of TCL-SPION or 
MION-47 separately for 3 days, and there was no effect on the cell growth velocity. The data are presented as the means ± standard 
errors from at least three independent experiments. Theranostics 2012, 2(1) 
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Figure 3. In vitro evaluation of cytokines release and nitric oxide production in macrophage. The levels of (A) IL-6 and (B) 
TNF-α released from mouse macrophage cells (RAW264.7). RAW264.7 cells were treated with TCL-SPION or MION-47 at concen-
trations of 25 µg Fe/mL and 50 µg Fe/mL for 24 hours. The IL-6 and TNF-α releases in the RAW264.7 cells were dose-dependently and 
significantly increased by adding TCL-SPION and MION-47 (*, P < 0.001, vs. control). MION-47 showed a greater stimulatory effect on 
IL-6 release than did TCL-SPION, while the TNF-α stimulatory effect was similar. (C) Nitric oxide production in macrophages. Mac-
rophages were treated TCL-SPION or MION-47 at concentrations of 25 µg Fe/mL, 50 µg Fe/mL and 100 µg Fe/mL for 24 hours. The 
nitrite levels were assayed by the Griess reaction. MION-47 induced a dose-dependent and significant increase in nitric oxide production 
(*, P < 0.001, vs. control), but TCL-SPION did not have any stimulatory effect on nitric oxide production. All data are presented as the 
means ± standard errors from at least three independent experiments. 
 
 
Mitochondrial membrane potential of macro-
phage 
The iron oxide-mediated stress impact on mac-
rophage  cells  was  determined  by  evaluating  the 
changes in mitochondrial membrane potentials using 
JC-1. Flow cytometry analysis revealed that treatment 
with TCL-SPION or MION-47 gradually reduced the 
population  of  healthy  cells  (red  fluorescence  in  the 
JC-1 assay, Fig. 4A) and caused a collapse of the mi-
tochondrial membrane potential (green fluorescence 
in the JC-1 assay) in a small population of RAW264.7 
cells after 24 hours (Fig. 4B). The H2O2 treatment (500 
µM) resulted in a collapse of the mitochondria mem-
brane potential in most cells within 2 hours (Fig. 4B). 
When comparing the influences of TCL-SPION and 
MION-47  on  the  mitochondrial  membrane,  the 
MION-47-treated  cells  emitted  more  green  fluores-
cence  than  did  those  treated  with  TCL-SPION,  im-
plying  that  MION-47  is  more  cytotoxic  than 
TCL-SPION (Fig. 4B).  
In vivo MR imaging 
For in vivo biodistribution study, we injected two 
USIPOs into the tail veins of the normal mice and the 
decrease in MR signal intensity was found in the liver 
and  spleen.  There  was  no  signal  drop  in  the  heart, 
kidney and brain (Supplementary Material:  data 3). 
When  we  compared  the  different  concentration  of 
TCL-SPION  and  MION-47  for  tumor  imaging,  MR 
images with 12.5 mg Fe/kg showed best tumor con-
trast. The tumors in subcutaneous layers appeared as 
hyperintense areas in T2*-weighted MR images before 
the injections (Fig. 5A). At 4 hours post-injection, no-
ticeable darkening appeared in the tumor areas, in-
dicating an accumulation  of TCL-SPION  within  the 
tumor (Fig. 5A). The changes in signal intensity were 
calculated  in  the  ROIs  of  the  T2*-weighted  images. 
The tumor signal intensity of the mice injected with 
TCL-SPION decreased by 33.0  1.3%, and this lower 
signal  intensity  was  maintained  at  24  hours 
post-injection (Fig. 5B, P < 0.01). However, no signif-
icant changes in post-injection signal intensity (7.5  
0.4%) were observed in the MION-47 group (Fig. 5B).  
We  tested  whether  Hep  G2  cells  take  up 
TCL-SPION and MION-47 after 24 hours of incuba-
tion in concentrations of 10, 100 and 500 µg Fe/mL. 
No uptake of TCL-SPION or MION-47 into the Hep 
G2 was detected (Supplementary Material: data 2A). 
Histological examination 
In normal mice, TCL-SPION and MION-47 were 
taken up by phagocytic cells of the liver and spleen, 
such  as  Kuffer  cells,  macrophages  and  monocytes 
whereas there were no accumulation of USPIO in the 
brain, heart and kidney tissue (Supplementary Mate-
rial: data 3).  Theranostics 2012, 2(1) 
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Figure 4. Mitochondrial membrane potential of macrophage. (A) Flow cytometry analysis of JC-1 in macrophages. Macrophages 
were treated with TCL-SPION or MION-47 at a concentration of 50 µg Fe/mL for 6 hours and 24 hours. The TCL-SPION and MION-47 
treatments gradually reduced the population of healthy cells (the JC-1 aggregates). (*, P < 0.05, vs. control) (B) Fluorescence image of JC-1 
aggregates (red) and JC-1 monomers (green) in macrophages. The MION-47 treated cells emitted more green fluorescence than did the 
TCL-SPION treated cells. All data are presented as the means ± standard errors from at least three independent experiments. 
 
 
 
Figure 5. In vivo MR imaging. (A) T2*-weighted images of tumor-bearing mice injected with 12.5 mg Fe/kg of TCL-SPION or MION-47. 
After injection with TCL-SPION, a noticeable darkening appeared in the tumor area, indicating a large accumulation of TCL-SPION within 
the tumor. In the mice injected with MION-47, there was no considerable difference in the pre-injection and post-injection tumor signal 
intensities. (B) The changes in signal intensity measured on T2*-weighted tumor images. The tumor signal intensity of the mice injected 
with TCL-SPION was decreased by 33.0  1.3%. MION-47 did not cause a significant change in signal intensity after injection (7.5  0.4%). 
(C) Prussian blue staining of tumor microsections. More TCL-SPION was accumulated in the tumors than MION-47. All data are pre-
sented as the means ± standard errors from at least three independent experiments. 
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Prussian  blue  staining  of  tumor  sections  was 
performed to examine the distribution of TCL-SPION 
and MION-47 in the  tumors. There  was greater ac-
cumulation of TCL-SPION than MION-47 in the tu-
mors (Fig. 5C). To further investigate the precise loca-
tion of the accumulated TCL-SPION and MION-47 in 
the tumors, we performed Prussian blue staining and 
CD  68  immunostaining  in  center  and  periphery  of 
tumor  section.  Immunohistological  analysis  showed 
that TCL-SPION and MION-47 were accumulated in 
center areas of tumors but not  periphery of the tu-
mors,  where  large  numbers  of  macrophages  were 
found (Data not shown). The greater accumulation of 
TCL-SPION than MION-47 was observed around the 
tumor blood vessels.  
Discussion 
Magnetic relaxivity of iron oxide nanoparticles is 
mainly  determined  by  iron  core  size,  composition, 
and crystalline phase. As compared mass magnetiza-
tion values with various-size magnetism-engineered 
iron  oxide  nanoparticles,  it  was  demonstrated  the 
smaller the nanoparticles, the weaker their net mag-
netic  moment  because  of  the  large  contribution  of 
canted magnetic spin states on the surface [29]. Fur-
thermore,  recent  paper  suggested  that  the  coating 
thickness and material of iron oxide nanoparticles can 
affected  the  R2  values  [21].  Among  these  physico-
chemical  parameters,  the  big  differences  between 
MION-47 and TCL-SPION are iron core size and sur-
face coating. On TEM images, the average core diam-
eter  of  TCL-SPION  was  9  nm  whereas  that  of 
MION-47 was 5 nm. In contrast to the prototype dex-
tran  coating  of  MION-47  [8,  30],  the  surface  of 
TCL-SPION was specifically modified with the pro-
tein-  or  cell-resistant  polymer,  poly(TMSMA-r- 
PEGMA-r-NAS)  [16].  In  our  study,  the  TCL-SPION 
(R2 = 345.0 ± 6.2 mM -1S-1) showed much higher relax-
ivity  than  that  of  the  MION-47  (R2  =  130.7  ±  1.1 
mM-1S-1), which were mainly determined by the large 
iron core sizes and might be affected by the different 
surface modification. 
Biocompatibility and minimal biofouling prop-
erties are the requirements that an MR contrast agent 
must meet to be successfully used in MR imaging in 
vivo. Therefore, it is necessary to engineer the surfaces 
of nanoparticles to minimize biofouling and aggrega-
tion under harsh physiological conditions (i.e., high 
salt  and  protein  concentrations)  [16,  31].  Consistent 
with previous reports [32, 33], there was no uptake of 
TCL-SPION or MION-47 by normal human cells, even 
at high concentrations, and hence no long-term cyto-
toxicity in normal human cells. Substantial amount of 
USPIO was taken by liver and spleen macrophages 
after  intravenous  injection  [34].  Upon  ingestion  of 
toxic substances, macrophages may release cytokines, 
such as TNF-α and IL-6, to induce further inflamma-
tory or immune responses [35]. In the present study, 
both TCL-SPION and MION-47 exposure stimulated 
the  production  TNF-α  and  IL-6  by  macrophages. 
There  was  greater  stimulation  of  TNF-α  release  by 
MION-47. When we investigated macrophage toxicity 
by a nitric oxide production assay, TCL-SPION did 
not stimulate nitric oxide production, while MION-47 
increased nitric oxide production remarkably. Nitric 
oxide is a highly reactive free radical and the role of 
nitric oxide in macrophage toxicity is well established 
[36].  In  the  present  study,  the  toxic  effect  of 
TCL-SPION  and  MION-47  on  the  mitochondrial 
function  of  macrophages  was  evaluated.  MION-47 
induced  more  collapses  of  the  mitochondrial  mem-
brane potential than did TCL-SPION. This result in-
dicates that MION-47 is more cytotoxic and can in-
duce more macrophage cell death than TCL-SPION.  
The  EPR  effect  allows  small  nanoparticles  to 
permeate the large fenestrations present in abnormal 
blood vessels of tumor [4, 37]. As a tumor-targeting 
strategy,  the  EPR  effect  of  nanoparticles  is  a  key 
mechanism for solid tumor targeting. The EPR effect 
is tunable by modifying the surface, charge or size of 
the nanoparticles or by manipulating the tumor mi-
croenvironment  [38,  39].  Modification  of  the  nano-
particle surface is important for improving the EPR 
effect as well as reducing the agglomeration of nano-
particles and proteins in body fluids. The TCL-SPION 
including multiple “protein-repelling” PEG groups in 
the cross-linked polymer coating layers indicated rel-
atively  high  protein  resistance  than  dextran-coated 
nanoparticles  in  the  serum-containing  physiological 
medium  [14].  Although  MION-47  is  similar  to 
TCL-SPION  in  size,  their  hydrophilic  dextran  coat 
may be susceptible to blood protein adsorption, thus 
reducing  the  dispersal  of  MION-47.  In  this  study, 
TCL-SPION was more accumulated than MION-47 in 
the tumors and most USPIOs were observed around 
the tumor blood vessels. Our study demonstrated that 
TCL-SPION  was  more  effective  in  tumor  targeting 
because of increased accumulation and high relaxivity 
of TCL-SPION as compared with MION-47.  
In  conclusion,  TCL-SPION  exhibited  lower  in 
vitro  cytotoxicity  and  better  tumor  MR  contrast  than 
MION-47. Our study suggests that TCL-SPION may 
be used as a new platform for in vivo tumor imaging 
and therapy monitoring. 
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